Share the commitment.
Help create a brighter future for people living with PPMS.
We invite you to consider participation in our innovative FENtrepid Study. Study participants will be part of a team of PPMS patients, clinicians and scientists seeking to determine whether an investigational new drug is a potentially superior treatment option.
The FENtrepid Study seeks to advance treatment for PPMS.
The FENtrepid Study is assessing how safe and effective an investigational study drug is in treating PPMS compared to ocrelizumab. No participants will receive only a placebo—a “dummy drug” that contains no active medicine. The study will last for approximately 3 years and 4 months.
Everyone who joins this clinical trial will be split into two groups randomly and receive either the investigational drug (fenebrutinib) or ocrelizumab.
Fenebrutinib will be given as tablets to take by mouth, twice a day, whereas ocrelizumab will be given as a drip into the vein (an intravenous infusion), once every six months.
You will have a 1 in 2 chance of receiving either:
- Two pills of fenebrutinib twice a day, as well as a “dummy” treatment that is given like an infusion of ocrelizumab every 24 weeks but contains no active ingredients
- An infusion of ocrelizumab every 24 weeks, as well as a “dummy” treatment that is given like two pills of fenebrutinib twice a day but contains no active ingredients
This is a “double-dummy” clinical trial, which means that both groups will be given treatments that look exactly the same so that doctors and patients cannot figure out which treatment each group is receiving.
Neither you nor your clinical trial doctor can choose or know the group you are in. However, your clinical trial doctor can find out which group you are in, if your safety is at risk.
You can leave this clinical trial at any time and you will not lose your access to regular care.
During the FENtrepid Study, you will need to visit a study clinic at least 20 times. This is so that we can monitor your general health and see how you are responding to your assigned study drug. On average, these visits will occur once every 3 months, however your first few visits will be more frequent than this.
You may discontinue study treatment at any time and continue to attend study visits. If so, you will stop receiving any study drug.